September 30, 2025
KANEKA CORPORATION

Social Bond Reporting

On December 2023, Kaneka issued a Social Bond (their 9th unsecured straight corporate bond) to raise funds for capital investment in the new Hokkaido Medical Device Plant. As the full amount of the funds raised has been allocated to the target project, we hereby report the allocation status of the funds and the impact reporting for the target project as follows.

1. Allotment of funds raised (as of end of June 2025)

(Millions of yen)

Amount issued	Net amount (*1)	Amount allotted (*2)	Non-allotted remainder
10,000	9,945	9, 945	—

(*1) The net amount is the amount resulting after subtracting the issuing charges from the amount issued.
(*2) Breakdown of the amount allotted.

	Scheduled to be allotted	Allotted	Non-allotted remainder
Facility funds	4,057	4,057	—
Facility funds before social bond issuance (refinance)	5,888	5,888	—
Total	9,945	9,945	—

2. Impact Reporting

Funds raised through the Social Bond were allocated to construct a new medical device plant in Hokkaido, where we produce adsorption type blood purification devices “Rheocarna™” and adsorption type plasma purification devices “Liposorber™”. The number of patients with arteriosclerosis obliterans (ASO) (*3), which these medical devices are intended to treat, is on the rise worldwide, along with increases in diabetes, chronic renal failure, and other conditions. Production at this facility contributes to maintaining patient health and reducing patient numbers.

Output	New construction and expansion of medical device manufacturing facilities	Construction of New Hokkaido Medical Device Plant
Outcome	Operational status of manufacturing facilities	Completed in August 2024, producing the adsorption type blood purification devices "Rheocarna™" and adsorption type plasma purification devices "Liposorber™" Kaneka Completes Construction of Medical Device Plant in Hokkaido｜KANEKA CORPORATION

(*3) A disease that causes arteriosclerosis where stenosis and occlusion of lower limbs artery occurred, leading to impaired blood flow (ischemia). In the early stages, it causes coldness, numbness, and gait disturbance. When the disease progresses to critical limb ischemia with pain and ulceration, the risk of leg amputation and death increases.

<About the external organization review>

Kaneka is scheduled to receive the review from Rating and Investment Information Inc. ("R&I"), and the results will be published through R&I's website*4.

(*4) The R&I website: Social Finance｜ESG Information ｜Rating and Investment Information, Inc.

＜Outline of the social bond＞

・Name: Unsecured Straight Bond No.9 of Kaneka Corporation
・Issue amount: 10 billion yen
・Issuance term: 5 years
・Issuance date: December 7, 2023
・Usage of funds: Capital investment in the Hokkaido Medical Device Plant
・Acquisition rating: A(R&I)

Related links: Kaneka Issues Social Bond｜KANEKA CORPORATION